Five Prime Therapeutics, Inc.
111 Oyster Point Boulevard
San Francisco
California
94080
United States
Website: http://www.fiveprime.com/
About Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) is a publicly traded, clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics to improve the lives of patients with serious diseases. We have an industry-leading and differentiated drug discovery platform. Our comprehensive proprietary libraries of the extracellular proteome, differentiated screening capabilities and protein therapeutic generation and engineering capabilities comprise a unique and powerful IND engine that positions us to discover novel pathways and targets in immuno-oncology and will continue to generate important development programs. Our success with our drug discovery platform has led to a pipeline that is on track to more than double to five development programs in clinical trials across multiple indications in 2018. We also have several undisclosed research programs at different points of the target validation and molecule generation phases that have the potential to yield our next wave of development-stage therapeutic biologics. And we continue to fuel this process at the earliest stages with new screens planned this year.
Five Prime is committed to innovation and outstanding science to develop effective new drugs for the treatment of severe diseases. We value our culture of openness, collaboration and productivity.
The company is in a strong financial position and has an effective executive team and Board of Directors. Discover more about Five Prime at www.fiveprime.com
Stock Symbol: FPRX
Stock Exchange: Nasdaq
246 articles about Five Prime Therapeutics, Inc.
-
The U.S. Attorney’s Office was busy indicting nine people for charges related to insider trading. Some charges were unrelated, but three were specific to the biopharma industry.
-
The government charged Chicago-based Daniel V.T. Catenacci, a medical school professor who served as the lead investigator of the company’s cancer drug bemarituzumab.
-
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics
4/16/2021
Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all outstanding shares of common stock of Five Prime Therapeutics (NASDAQ:FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies, for $38.00 per share in cash
-
Five Prime Cancels Fourth Quarter and Full-Year 2020 Financial Results Conference Call
3/9/2021
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for Wednesday, March 10, 2021 at 1:30 p.m. PT / 4:30 p.m. ET.
-
Shares of Five Prime Therapeutics were soaring this morning after Amgen announced it was acquiring the company and its Phase III ready anti-FGFR2b antibody bemarituzumab for $1.9 billion in cash.
-
Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call
3/2/2021
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), will report its fourth quarter and full year 2020 operational and financial results on Wednesday, March 10, 2021 after the U.S. financial markets close.
-
Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference
2/26/2021
Five Prime Therapeutics, Inc. announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer are scheduled to participate in a fireside chat at the Cowen 41st Annual Health Care Conference on Thursday, March 4, 2021 at 10:30 a.m. ET / 7:30 a.m. PT.
-
Five Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference
2/22/2021
Five Prime Therapeutics to Participate in the SVB Leerink 10 th Annual Global Healthcare Conference
-
Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day
2/5/2021
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) today announced that Tom Civik, President and Chief Executive Officer, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer, are scheduled to participate in a fireside chat at the virtual Guggenheim Healthcare Talks: Oncology Day on Friday, February 12, 2021 at 1:00 p.m. ET/10:00 a.m. PT.
-
Phase 2 FIGHT Trial Results Presented at ASCO GI Validate Importance of FGFR2b Overexpression and Reinforce Potential of Bemarituzumab Plus Chemotherapy as a Frontline Targeted Treatment for FGFR2b+ Gastric and GEJ Cancers
1/15/2021
All three efficacy endpoints (PFS, OS and ORR) in the FIGHT Phase 2 trial met pre-specified statistical significance 2021 priorities for the bemarituzumab program include collaborating with regulatory agencies on next steps, initiating a global Phase 3 trial in gastric and GEJ cancers and evaluating bemarituzumab in other epithelial cancers that overexpress FGFR2b
-
Five Prime to Present Phase 2 FIGHT Trial Results of Bemarituzumab at American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Virtual Annual Symposium
12/9/2020
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced that detailed results from the global, randomized, double-blind placebo-controlled Phase 2 FIGHT trial evaluating bemarituzumab plus mFOLFOX6 chemotherapy in patients with fibroblast growth factor receptor 2b-positive (FGFR2b+),
-
Five Prime Announces Pricing of Upsized Public Offering of Common Stock - Nov 13, 2020
11/13/2020
Five Prime Therapeutics, Inc., announced the pricing of an underwritten public offering of 7,200,000 shares of its common stock at a price to the public of $21.00 per share.
-
Five Prime Therapeutics Inc., in collaboration Zai Lab Limited on the development bemarituzumab, a novel therapy for front-line advanced non HER2+ gastric or gastroesophageal junction (GEJ) cancer, on Wednesday announced groundbreaking positive topline Phase II results.
-
Five Prime Presents First Preclinical Data on Anti-CCR8 Antibody FPA157
11/11/2020
Preclinical data support evaluation of FPA157 as a novel immunomodulator with the potential to remove Treg-mediated immune suppression in solid tumors FPA157 is an anti-CCR8 antibody engineered to enhance antibody-dependent cell-mediated cytotoxicity to preferentially eliminate CCR8+ Treg cells in the tumor microenvironment
-
Five Prime Announces Proposed Public Offering of Common Stock - Nov 11, 2020
11/11/2020
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, announced that it plans to offer and sell, subject to market and other conditions, 5,000,000 shares of its common stock in an underwritten public offering.
-
Five Prime Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit Compared to Placebo Plus Chemotherapy in Front-Line Advanced Gastric and Gastroesophageal Junction Cancer
11/10/2020
All 3 efficacy endpoints in the Global Phase 2 FIGHT trial met pre-specified statistical significance Median progression-free survival (PFS) improved from 7.4 months to 9.5 months. Hazard ratio (HR) 0.68 (95% CI: 0.44-1.04) p=0.073 Median overall survival (OS) improved from 12.9 months to not reached. HR 0.58 (95% CI: 0.35-0.95) p=0.027 Overall response rate (ORR) improved by 13.1% (p=0.106)
-
Five Prime Therapeutics Reports Third Quarter 2020 Results
11/3/2020
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced results for the third quarter of 2020 in addition to providing an update on the company’s recent activities.
-
Five Prime to Present First Preclinical Data of Anti-CCR8 Antibody FPA157 at Society for Immunotherapy of Cancer Virtual Annual Meeting
11/2/2020
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced the upcoming virtual poster presentation of the first preclinical data from its anti-CCR8 antibody, FPA157 program, at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting being held from November 9-14, 2020.
-
Five Prime Therapeutics Announces Timing of Its Third Quarter 2020 Results Conference Call
10/28/2020
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its third quarter 2020 operational and financial results on Tuesday, November 3, 2020 after the U.S. financial markets close.
-
Five Prime Therapeutics to Participate in the 2020 Wells Fargo Virtual Healthcare Conference
9/9/2020
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced that Tom Civik, Chief Executive Officer of Five Prime Therapeutics, and Helen Collins, M.D., Executive Vice President and Chief Medical Officer of Five Prime Therapeutics